Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
SYSTEMIC MANAGEMENT OF BREAST CANCER Dr Alice Musibi Medical Oncologist KENYATTA NATIONAL HOSPITAL BREAST CANCER INTRODUCTION • Is one of the deadliest and most common cancers ailing women all over the world • In Australia 1 in 13 women will develop ca breast at sometime in her life • In USA 215,990 women will be found to have invasive ca breast in 2004 • More common in older than younger women with average age of diagnosis of 64 years CANCER IN NAIROBI (KENYA) • A total of 2,716 cases were registered, comprising of 1246 men and 1470 women between 2000-2003 • Breast cancer was leading with 22.9% followed by cervical cancer with 19.3% • The mean age of diagnosis was 45 years Most C ommon C ance rs for all C ase s Re giste re d (2000 - 2002) Male IC D-10 C 00-C 14,C 30-C 32 & C 73 He a d & ne c k Female 14.8 C 15 Oe s o pha gus 7.2 10.0 C 16 S to m a c h 4.4 7.1 3.3 3.4 C 18 C o lo n C 22 Live r 2.0 5.7 C 44 Othe r S kin 2.1 3.7 C 46 Ka po s i s a rc o m a 2.6 6.9 2.4 C 50 B re a s t 0.9 23.3 C 53 C e rvix Ute ri 20.0 C 56 Ova ry 3.3 C 61 P ro s ta te 9.4 C 69 Eye 3.0 C 82-C 85;C 96 No n-Ho dgkin lym pho m a 2.1 4.2 20.0 15.0 10.0 5.0 2.4 0.0 5.0 10.0 15.0 Pe rce ntage (%) of All C ase s 20.0 25.0 30.0 BREAST CANCER TREND IN NAIROBI 60 50 No of cases 40 Breast 30 Cervix uteri 20 10 0 4 0- 5 to 9 10 to 14 9 4 9 4 9 4 9 4 9 4 9 4 9 5 -1 0 -2 5 -2 0 -3 5 -3 0 -4 5 -4 0 -5 5 -5 0 -6 5 -6 0 -7 5 -7 0 -8 5 1 2 2 3 3 4 4 5 5 6 6 7 7 8 Age-group Treatment • Local management – 18th century – Louis Petit of France - total mastectomy and excision of axillary's lymph nodes – 1895 - William Halstead popularized radical mastectomy – Harvey Cushing - extended radical - internal mammary chain excised after splitting the mediastinum – 1923-1937 - local excision and radium needles. – Conventional radiotherapy Out-come • Poor overall results of survival • Frequent local recurrence and distant metastases • Treatment worse than disease • Concept of quality life • Women’s insistence for breast preservation Treatment • Multidisciplinary – Surgery – Chemotherapy, hormonal therapy, immunotherapy – Radiation therapy – Palliative therapy – Occupational/physioth erapy • Lymph edema therapy – etc Systemic therapy • Types – Primary induction therapy – Neo-adjuvant chemotherapy – Adjuvant chemotherapy – Palliative • Associated with – a decrease in the death rate – prolonged relapsefree survivals • Acute and chronic side effects Systemic therapy- combination – Maximum cell kill – Tolerable range of toxicity for each drug – Broader range of interaction between drugs and tumor cells – Less chance of developing cellular drug resistance Adjuvant systemic therapy • For patients at risk of disease • • • • recurrence after treatment of primary tumior Known tumor or maximum bulk should be removed Chemotherapy started as soon as possible post op Effective chemotherapy must be used at maximally tolerated doses Usually for a period (6-8 cycles) • Milan CMF trial (overview)- – CMF vs. surgery alone • Relapse free survivalmedian 19.4 – benefits in pre-menopausal patients (Bonnadona G et al N Engl. J Med 1995;332;901) Neo-adjuvant chemotherapy • Systemic therapy given preoperatively – Advantage • Early exposure to micro- • • metastasis Tumor response measurable Reduce tumor bulk so less extensive surgery – Disadvantage • May delay surgery in • tumors which may turn out to be chemo-resistant May obscure real extent of disease Choice of treatment regime • Depends on prognostic factors for – – – – – – recurrence/survival Age tumour size, nodal status histologic grade, hormone receptors, ??Her-2/neu overexpression (about 40% of breast cancers) – ?Lymphatic/vascular invasion) – Estimated benefit of therapy in terms of absolute risk reduction of relapse and death. – Estimation of the toxicity associated with therapy – [COST] Prognosis • Five year relative survival is dependent on the stage of breast cancer at diagnosis Stage Survival rate 0 100% I 98% IIA 88% IIB 76% IIIA 56% IIIB 49% IV 16% *(Overview American Cancer Society –2003)* Post-surgical Mx of breast cancer (KNH) [1989-2000] • Surgery 374 patients • Chemotherapy – Adjuvant – Metastatic 22 (5.8%) -21 – Adjuvant – Palliation - • Radiotherapy 46 (12.4%) 53 • Hormone therapy (tamoxifen) (33.7%) - 126 • East African Medical Journal: 2002 79(3): 156-162 Metastatic breast cancer (MBC) • MBC is considered an incurable disease. • majority of patients with MBC do not survive beyond 5 years after diagnosis. • Treatment usually is palliative with systemic therapy including – chemotherapy – hormonal treatment – biologic therapy (e.g. Trastuzumab) • Pain control MBC -2 • The surgery of breast tumors with distant metastases has been indicated to – prevent local complications (toilet surgery) – Removal of the metastatic lesions in selected patients (single brain, liver, bone or pulmonary lesions). • Surgery of the primary tumor can actually improve survival of metastatic breast cancer. – especially in patients with only bone metastases • (JCO, Vol 24, No 18 (June 20), 2006: pp. 2743-2749) Many of our women are presenting like this!! Language Lack of medical insurance Poverty Fears False beliefs Fatalism Lack of information Knowledge Attitude Behavior Risk factors • Normal lifetime risk of developing breast cancer in white women is 1 in 8 or 9 • There is no family history in over 75% of patients • Most women with breast cancer do not have any identifiable risk factors Risk factors • Age • Ethnicity – more cancer in white • • • • women but more mortality in blacks Family history of breast cancer Previous history of personal breast cancer gives 1-2% risk of contralateral breast cancer/year Previous history of ovarian or endometrial cancers Prolonged estrogen exposure – – – Early menarche (under age 12)/late menopause (after age 50) Late first pregnancy/nulliparous/no fullterm pregnancy (1.5 times higher incidence) Hormone replacement therapy especially high estrogen based pills but more so the combined pills • Genetic predisposition • BRCA1 (85%) • BRCA2 • p53 gene – 1% in women with cancer of breast below 40 years • Lifestyle factors – – – – – Dietary factors – particularly increased fat consumption Obesity Lack of exercise Alcohol consumption Smoking (???) • Prior Radiation therapy • Atypical epithelial hyperplasia of the • • breast Fibrocystic disease with proliferative changes Lobular carcinoma in situ (LCIS) Recommendations GovernmentAcknowledge the volcano in cancer Policy National guidelines Clinical practice guidelines Recommendations • Clinical breast • • • • examination U/S Mammography MRI scans of breast Genetic mapping Recommendations • Facilities – Cancer centres – 1 (KNH) – Laboratories • ordinary histopathology • immunohistochemical studies – KEMRI mainly research purposes – Private hosp (Nbi, AKUH) – all send the specimens to SA or Italy – Radiotherapy units – 2 MEDICAL ONCOLOGY RADIOTHERAPY PATHOLOGY RADIOLOGY SURGEONS AND ORGAN SPECIALISTS